AR029178A1 - Compuesto antagonista selectivo del receptor de adenosina a2b, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento - Google Patents
Compuesto antagonista selectivo del receptor de adenosina a2b, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamentoInfo
- Publication number
- AR029178A1 AR029178A1 ARP000104523A ARP000104523A AR029178A1 AR 029178 A1 AR029178 A1 AR 029178A1 AR P000104523 A ARP000104523 A AR P000104523A AR P000104523 A ARP000104523 A AR P000104523A AR 029178 A1 AR029178 A1 AR 029178A1
- Authority
- AR
- Argentina
- Prior art keywords
- adenosine
- manufacture
- antagonist compound
- receiver
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 101150078577 Adora2b gene Proteins 0.000 abstract 2
- 206010012735 Diarrhoea Diseases 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 208000025698 brain inflammatory disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 abstract 1
- 210000002460 smooth muscle Anatomy 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
Abstract
Un compuesto antagonista selectivo del receptor de adenosina A2B de la formula (1), en donde R es un grupo amina alifático o cicloalifático, o una sal farmacéuticamente aceptable del mismo, y una sal farmacéuticamente aceptable del mismo. Los compuestos de formula (1) se pueden usar para tratar, entre otras indicaciones, asma y diarrea. Además se describen composiciones farmacéuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para antagonizar los receptores de adenosina A2B, para tratar asma, diarrea, regulacion del tono del musculo liso, tratamiento de desordenes inflamatorios del tracto gastrointestinal, el tratamiento de la enfermedad de Alzheimer, de Parkinson, demencia, de presion, o dano cerebral traumático, enfermedades inflamatorias, y otras como esclerosis multiple, sepsis, osteoporosis, entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15164999P | 1999-08-31 | 1999-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029178A1 true AR029178A1 (es) | 2003-06-18 |
Family
ID=22539669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104523A AR029178A1 (es) | 1999-08-31 | 2000-08-30 | Compuesto antagonista selectivo del receptor de adenosina a2b, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1208100B1 (es) |
| JP (1) | JP3914434B2 (es) |
| KR (1) | KR100502757B1 (es) |
| CN (1) | CN1178940C (es) |
| AR (1) | AR029178A1 (es) |
| AT (1) | ATE236160T1 (es) |
| AU (1) | AU760071B2 (es) |
| BR (1) | BR0013673A (es) |
| CA (1) | CA2383351C (es) |
| DE (1) | DE60001969T2 (es) |
| DK (1) | DK1208100T3 (es) |
| ES (1) | ES2190422T3 (es) |
| HK (1) | HK1049835B (es) |
| IL (2) | IL148366A0 (es) |
| MX (1) | MXPA02002262A (es) |
| NO (1) | NO328489B1 (es) |
| NZ (1) | NZ517546A (es) |
| PT (1) | PT1208100E (es) |
| TR (1) | TR200201132T2 (es) |
| TW (1) | TWI262921B (es) |
| WO (1) | WO2001016134A1 (es) |
| ZA (1) | ZA200201650B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| AU2001238665A1 (en) | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
| WO2003002566A1 (en) * | 2001-06-29 | 2003-01-09 | Cv Therapeutics, Inc. | Purine derivatives as a2b adenosine receptor antagonists |
| US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
| ATE410168T1 (de) * | 2003-07-22 | 2008-10-15 | Cv Therapeutics Inc | A1 adenosin-rezeptor-antagonisten |
| JPWO2005053695A1 (ja) * | 2003-12-04 | 2007-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 多発性硬化症予防剤または治療剤 |
| WO2005077950A2 (en) * | 2004-02-14 | 2005-08-25 | Smithkline Beecham Corporation | Medicaments with hm74a receptor activity |
| NZ554485A (en) * | 2004-10-15 | 2010-12-24 | Gilead Palo Alto Inc | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
| AU2005295437B2 (en) | 2004-10-20 | 2011-05-19 | Gilead Palo Alto, Inc. | Use of A2A adenosine receptor agonists |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| KR101494125B1 (ko) | 2006-02-03 | 2015-02-16 | 길리애드 사이언시즈, 인코포레이티드 | Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법 |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
| DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
| WO2017106352A1 (en) | 2015-12-14 | 2017-06-22 | Raze Therapeutics, Inc. | Caffeine inhibitors of mthfd2 and uses thereof |
| JOP20210164A1 (ar) | 2019-01-11 | 2023-01-30 | Omeros Corp | طرق وتركيبات علاج السرطان |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7810946L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | Metod att behandla kronisk obstruktiv luftvegssjukdom |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| AU649091B2 (en) * | 1990-12-21 | 1994-05-12 | Beecham Group Plc | Xanthine derivatives |
| GB9210839D0 (en) * | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
-
2000
- 2000-08-28 ES ES00971055T patent/ES2190422T3/es not_active Expired - Lifetime
- 2000-08-28 DK DK00971055T patent/DK1208100T3/da active
- 2000-08-28 EP EP00971055A patent/EP1208100B1/en not_active Expired - Lifetime
- 2000-08-28 AT AT00971055T patent/ATE236160T1/de not_active IP Right Cessation
- 2000-08-28 IL IL14836600A patent/IL148366A0/xx active IP Right Grant
- 2000-08-28 AU AU80348/00A patent/AU760071B2/en not_active Ceased
- 2000-08-28 CN CNB00813717XA patent/CN1178940C/zh not_active Expired - Fee Related
- 2000-08-28 NZ NZ517546A patent/NZ517546A/en unknown
- 2000-08-28 JP JP2001519700A patent/JP3914434B2/ja not_active Expired - Fee Related
- 2000-08-28 HK HK03101920.0A patent/HK1049835B/zh not_active IP Right Cessation
- 2000-08-28 DE DE60001969T patent/DE60001969T2/de not_active Expired - Lifetime
- 2000-08-28 WO PCT/US2000/040751 patent/WO2001016134A1/en not_active Ceased
- 2000-08-28 BR BR0013673-5A patent/BR0013673A/pt not_active Application Discontinuation
- 2000-08-28 CA CA002383351A patent/CA2383351C/en not_active Expired - Fee Related
- 2000-08-28 KR KR10-2002-7002718A patent/KR100502757B1/ko not_active Expired - Fee Related
- 2000-08-28 PT PT00971055T patent/PT1208100E/pt unknown
- 2000-08-28 MX MXPA02002262A patent/MXPA02002262A/es active IP Right Grant
- 2000-08-28 TR TR2002/01132T patent/TR200201132T2/xx unknown
- 2000-08-30 AR ARP000104523A patent/AR029178A1/es active IP Right Grant
- 2000-09-21 TW TW089117772A patent/TWI262921B/zh not_active IP Right Cessation
-
2002
- 2002-02-25 IL IL148366A patent/IL148366A/en not_active IP Right Cessation
- 2002-02-27 ZA ZA200201650A patent/ZA200201650B/en unknown
- 2002-02-27 NO NO20020979A patent/NO328489B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100502757B1 (ko) | 2005-07-22 |
| NO20020979D0 (no) | 2002-02-27 |
| CA2383351A1 (en) | 2001-03-08 |
| AU8034800A (en) | 2001-03-26 |
| DK1208100T3 (da) | 2003-06-30 |
| JP3914434B2 (ja) | 2007-05-16 |
| HK1049835A1 (en) | 2003-05-30 |
| KR20020041419A (ko) | 2002-06-01 |
| JP2003508398A (ja) | 2003-03-04 |
| ZA200201650B (en) | 2003-05-28 |
| PT1208100E (pt) | 2003-07-31 |
| AU760071B2 (en) | 2003-05-08 |
| ATE236160T1 (de) | 2003-04-15 |
| IL148366A (en) | 2006-12-10 |
| EP1208100B1 (en) | 2003-04-02 |
| MXPA02002262A (es) | 2002-09-30 |
| NZ517546A (en) | 2003-10-31 |
| WO2001016134A1 (en) | 2001-03-08 |
| IL148366A0 (en) | 2002-09-12 |
| CN1377352A (zh) | 2002-10-30 |
| CN1178940C (zh) | 2004-12-08 |
| NO328489B1 (no) | 2010-03-01 |
| CA2383351C (en) | 2005-11-01 |
| DE60001969D1 (de) | 2003-05-08 |
| BR0013673A (pt) | 2002-05-28 |
| EP1208100A1 (en) | 2002-05-29 |
| DE60001969T2 (de) | 2004-02-05 |
| HK1049835B (zh) | 2005-04-08 |
| TR200201132T2 (tr) | 2002-08-21 |
| TWI262921B (en) | 2006-10-01 |
| NO20020979L (no) | 2002-04-26 |
| ES2190422T3 (es) | 2003-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029178A1 (es) | Compuesto antagonista selectivo del receptor de adenosina a2b, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento | |
| ES2158814B1 (es) | Derivados de pirrolidina antagonistas del receptor ccr-3 | |
| WO2004007481A3 (en) | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders | |
| WO2002068406A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
| MXPA04005444A (es) | Ureas de 2-aminobenzotiazoles como moduladores de adenosina. | |
| AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
| UY27092A1 (es) | Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen | |
| UY26728A1 (es) | Derivados de la benzocicloalquilenilamina como antagonistas de los receptores muscarínicos | |
| MY136034A (en) | New medicaments for the treatment of chronic obstructive pulmonary disease | |
| WO2008154083A3 (en) | Compounds, compositions and methods for the treatment of synucleinopathies | |
| MY140835A (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| IL146403A0 (en) | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | |
| IL166918A (en) | Aza-bicycloalkyl sites, medicinal preparations containing them and their use in the preparation of drugs for the treatment and prevention of psychotic and neurodegenerative disorders | |
| PT1259489E (pt) | Compostos azapoliciclicos condensados con arilo. | |
| AR021893A1 (es) | Compuesto de 2-fenil-1-(3,4-dihidroxi-5-nitrofenil)-1-etanona sustituida , su uso para la manufactura de un medicamento en el tratamiento de algunos trastornos del sistema nervioso central y periférico y composiciones farmacéuticas que las contienen | |
| ES2160525B1 (es) | Derivados de la 4-aroilpiperidina antagonistas de los receptores ccr-3 | |
| CL2004000848A1 (es) | Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras | |
| MX9300616A (es) | Compuestos antagonistas del receptor 5-hidroxitriptamina, proceso para su prepararcion y composicion farmaceutica que los contiene | |
| EP1284257A3 (en) | Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter | |
| JP2005514457A5 (es) | ||
| MX2009010165A (es) | Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704. | |
| PH12021553056A1 (en) | Modified release formulations and uses thereof | |
| SE0102055D0 (sv) | New Compounds | |
| UY26720A1 (es) | Derivados del pirrol | |
| AR005102A1 (es) | Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |